Pooled analyses from the Adjuvant Treatment of Colon Cancer trial suggest that most patients with stage III colon cancer develop recurrence within the first 3 years following treatment. Improved disease-free survival and improved overall survival were observed for such patients who were treated with adjuvant combination therapy of 5-fluorouracil, leucovorin and oxaliplatin versus those treated with 5-fluorouracil and leucovorin.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Andre, T. et al. Oxaliplatin, fluorouracil and leucovorin as adjuvant treatment for colon cancer. N. Engl. J. Med. 350, 2343–2351 (2004).
Andre, T. et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J. Clin. Oncol. 27, 3109–3116 (2009).
Sargent, D. et al. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. J. Clin. Oncol. 23, 8664–8670 (2005).
Sargent, D. et al. End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT group. J. Clin. Oncol. 25, 4569–4574 (2007).
Sargent, D. et al. Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. J. Clin. Oncol. 27, 872–877 (2009).
Kuebler, J. et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J. Clin. Oncol. 25, 2198–2204 (2007).
Wolmark, N. et al. A phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: survival results of the NSABP protocol C-07. J. Clin. Oncol. 26 (Suppl.), 4005 (2008).
Sargent, D. et al. Use of two-year disease-free survival (DFS) as a primary endpoint in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: new data on 12,676 patients from MOSAIC, X-ACT, PETACC-3, NSAPB C-06 and C-07, and C89803. J. Clin. Oncol. 27, 4011 (2009).
Engstrom, P. et al. Colon cancer guidelines. J. Natl Compr. Cancer Netw. 5, 884–925 (2007).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares he is a consultant for and a recipient of grant/research support from Sanofi-Aventis.
Rights and permissions
About this article
Cite this article
Benson, A. Adding oxaliplatin to the equation. Nat Rev Clin Oncol 6, 620–622 (2009). https://doi.org/10.1038/nrclinonc.2009.162
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2009.162
This article is cited by
-
Animal Models to Test Adjuvant Treatment: An Experimental Model of Colon Cancer
Current Colorectal Cancer Reports (2013)
